MarketInOut Stock Screener Log In | Sign Up

Armata Pharmaceuticals Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/30/2026
Armata Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization121.03 mln
Float11.90 mln
Earnings Date11/18/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-11.32
Highly reliable

Relative Strength

21 / 100
Significantly lagging

Pre-Tax Margin

-3,467%
Severely loss-making

ROE

89.70
Exceptional

Altman Z-Score

-17.39
Deeply distressed

Business Description

Armata Pharmaceuticals is a Los Angeles-based drug development company working on new treatments for dangerous bacterial infections that no longer respond to standard antibiotics. Rather than using conventional antibiotics, the company harnesses bacteriophages ? naturally occurring viruses that can seek out and destroy specific bacteria ? to fight infections caused by organisms such as Staphylococcus aureus and Pseudomonas aeruginosa. Armata works alongside pharmaceutical giant Merck to explore additional applications of this technology and operates as part of the Innoviva group of companies.

Key Fundamentals

EPS-5.29
ROE89.70
RPS0.15
ROIC-20.33
ROA-231
Interest Cover-1.90
EBITDA, mln-169
EV / EBITDA-3.44
EV / EBIT-3.40
Revenue, mln5.54
EV / Revenue105

Quote Details

Last 3.28
Change 0.03 (0.92%)
Open 3.39
Volume 46,741
Turnover 153,310
Average Volume 100,192

Financial Ratios

Pre-Tax Profit Margin-3,467
Current Ratio0.11
Price / Sales28.14

Financial Strength

Altman Z-Score-17.39
Piotroski F-Score 3 / 9
Beneish M-Score-11.32
Short Ratio5.78
Short % of Float7.99

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -9.89% 4 / 100   
1 Month -0.91% 38 / 100   
2 Months -36.31% 3 / 100   
6 Months -63.1% 2 / 100   
1 Year -39.93% 7 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog